Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


E-learning: Update on Renal cell carcinoma with prof. Camillo Porta

During a special Speaker Tour meeting prof. Camillo Porta visited the NKI-AVL to discuss challenges and best practices within the changing treatment landscape in (m)RCC. 

‘With the development of new therapeutic systemic options for the treatment of mRCC, including immunotherapy, novel TKIs and combination treatment, we find ourselves standing at the verge of a new era of therapeutic possibilities.  Our challenge is to find the best possible treatment algorithm for each (m)RCC patient.’

Topics that are discussed in this e-learning are:

  • When are we ready for adjuvant therapy?
  • What is the role of cytoreductive nephrectomy in mRCC?
  • How to choose from the available options for first, second, and third line treatment?
  • What may be the impact of immunotherapy and novel TKIs on the treatment algorithm?

Chair and co-discussant: prof. J. Haanen, medical oncologist, NKI-AVL

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 22/03/2018

ASCO GU 2018: Progression after IO combination regimens mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined the clinical outcome of patients with metastatic renal cell carcinoma progressing on frontline immune-oncology based combination regimens.

Congresnieuws 22/03/2018

ASCO GU 2018: Renal Cell Carcinoma News Program

This year the ASCO Genitourinary Cancers Symposium took place in San Francisco from February 8th - 10th. In this Renal Cell Carcinoma News Program, we focus on the highlights for RCC at this congress. Moderator Catherine Hood and a panel of international experts discuss the following topics: Adjuvant systemic therapy Cabozantinib in the first line treatment of metastatic RCC The NIVOREN trial that investigates nivolumab in a ‘real world setting’ Combination treatments with VEGF and PD1/PD-L1 inhibition Advances in treatment for papillary RCC Speakers: Prof. Joaquim Bellmunt, MD, medical oncologist, Dana-Farber/Brigham and Women's Cancer Center, Boston Daniel George, MD, medical oncologist, Duke Cancer Center, Durham Jeanny Aragon-Ching, MD, medical oncologist, Inova Fairfax hospital, Fairfax Sumanta Pal, MD, medical oncologist, City of Hope Comprehensive Cancer Center, Duarte Moderator: Catherine Hood

Quarterly focus 12/09/2018

E-learning: Quarterly Focus on Genitourinary Cancer | RCC

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Oncology has developed a new program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data. In this second episode of the Quarterly Focus on Genitourinary Cancer, two pivotal, international publications on Renal Cell Carcinoma from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. The expert panel consist of: Prof. John Haanen, MD, PhD, medical oncologist, Netherlands Cancer Institute, Amsterdam Hans Westgeest, MD, medical oncologist, Amphia Ziekenhuis, Breda Astrid van der Veldt, MD, PhD, medical oncologist, Erasmus MC, Rotterdam Program: Invited speaker: Kathleen Mahoney, MD, PhD, medical oncologist, Beth Israel Deaconess Medical Center, Boston Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma N Engl J Med 378, 2018 Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma Nature Medicine 24, 2018

Congresnieuws 22/03/2018

ASCO GU 2018: Oligoprogressive mRCC

Pedro Barata, experimental therapeutics clinical fellow at the Taussig Cancer Institute Cleveland Clinic, explains the design and results of the trial he presented during the poster session. This retrospective study examined what the impact was of switching systemic treatment after radiosurgery for oligoprogressive, metastatic renal cell carcinoma.

Congresnieuws 22/03/2018

ASCO GU 2017: RCC news

On February 16-18, the 2017 Genitourinary Cancers Symposium took place in Orlando, Florida. The final congress day was dedicated to renal cell carcinoma. A panel of American experts will bring you the day’s highlights, which include: circulating tumor DNA frontline systemic therapy (CABOSUN, IMmotion) TKI+immunotherapy active surveillance in localized and advanced disease imaging and biomarkers for the diagnosis and monitoring of RCC cryoablation adjuvant treatment for localized tumors (ASSURE, S-TRAC) hereditary renal cancer Speakers: Prof. Eric Jonasch MD, medical oncologist, University of Texas MD Anderson cancer center, Houston TX Sumanta Pal MD, medical oncologist, City of Hope, Duarte CA Prof. Mohamad Allaf MD, urologic oncologist, John Hopkins School of Medicine, Baltimore MD Moderator: Catherine Hood PhD The news program includes an interview with prof. Thomas Powles (Barts and the London School of Medicine, UK) on the results of the IMmotion trial and his expectations for the future of atezolizumab in RCC.

Congresnieuws 13/12/2018

EMUC 2018: Frail patients and the CARMENA trial

Dr. Umberto Capitanio, urologist at the IRCCS Ospedale San Raffaele in Italy and chief editor of the kidney cancer section of the UROONCO educational platform, talks about the EMUC 2018 discussion about frail patients. Furthermore he mentions the discussion about the Carmena trial in which nephrectomy plus adjuvant sunitinib is compared to sunitinib alone in patients with metastatic renal cell cancer.

Congresnieuws 12/03/2015

Oncology News Program at Genitourinary Cancers Symposium 2015

The 2015 Genitourinary Cancers Symposium was held in Orlando from February 26th to 28th. In a multidisciplinary Oncology News Program Dutch and Belgian experts will discuss new important data, presented at this congress. In the first part of this Oncology News Program Dr. Thierry Gil, Prof. Jeroen van Moorselaar and Dr. Fons van den Bergh talk about the role of Androgen Deprivation Therapy in early and intermediate risk prostate cancer, dose escalation in Radiotherapy, Stereotactic Body Radiotherapy and possible predictive markers like Slco2B1 and androgen receptor splice variant 7. The second part covers the following topics on prostate cancer: Active Surveillance in early stage prostate cancer, Brachytherapy versus External Beam Radiation Therapy, active immunotherapy and check point inhibitors and one of the highlights of this congress, the GETUG-15 trial. These data are discussed by Prof. Winald Gerritsen, Prof. Gert De Meerleer and Prof. Thierry Roumeguère. The panel for the last part of this Oncology News Program consists of Prof. Gerritsen, Prof. van Moorselaar and Prof. Roumeguère. The experts discuss important new data on GU-non prostate cancer: organ sparing versus radical cystectomy, (neo)adjuvant chemotherapy in bladder cancer, the role of profiling urothelial cancer, anti-PDL1 and Pazopanib in combination with Paclitaxel in refractory urothelial cancer. Presented by dr. Ayan Panja.

Congresnieuws 12/09/2017

ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.